Navigation Links
Cytos Biotechnology Strengthens Management Team
Date:3/11/2013

ZURICH, March 12, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) today announced the appointment of Matthias Alder as Executive Vice President for Corporate Development and Legal Affairs and Cheryl Lassen as Vice President for Clinical Development. Philipp Mueller , Executive Vice President Clinical Development, will retire at the end of March 2013.

"We welcome Matthias Alder and Cheryl Lassen to our team. They bring significant additional experience and leadership to Cytos, which we believe will be critical to shape and execute our CYT003 program and corporate strategy," commented Christian Itin , PhD, CEO and Chairman of Cytos, and continued: "We thank Philipp Mueller for his many contributions and in particular for his work on the CYT003 program in allergic asthma and rhinitis, which forms the basis and focus of Cytos today. We are very grateful that Philipp will continue to work with Cytos as a consultant and wish him all the best for his future."

Matthias Alder joins Cytos as Executive Vice President Corporate Development and Legal Affairs. He has more than 19 years' of business, transactional and legal experience in the pharmaceutical and biotechnology industries. Most recently, he served as Senior Vice President Administration, General Counsel and Secretary of Micromet, Inc., a formerly Nasdaq-listed biopharmaceutical company located in Rockville, MD and Munich, Germany that was acquired by Amgen in 2012 for US$1.2 billion in cash. Prior to joining Micromet, he was a partner in the Life Sciences Transactions Practice at Cooley LLP, a renowned technology and life sciences-focused US law firm, where he specialized in representing biotech companies in strategic transactions with pharmaceutical companies. Earlier in his career, Mr. Alder was in-house counsel at Ciba-Geigy and Novartis. He holds law degrees from the University of Basel and the University of Miami (Florida), and is qualified to practice law in Switzerland and the United States.

Matthias Alder commented: "This is an exciting time to join Cytos. The company's lead program CYT003 has already achieved clinical proof of concept and the underlying product platform has multiple additional applications. I am looking forward to support building Cytos into one of the premier biotech companies in the vaccines and immunotherapy space."

Cheryl Lassen , MD, joins Cytos as Vice President Clinical Development, bringing a wealth of clinical development experience, with particular expertise in respiratory diseases. Dr. Lassen joins Cytos from Novartis where she was Program Leader for the global clinical development of the indacaterol program, a product since approved by the US FDA, EMA, Japan and many countries worldwide. In her 20 year career, she has worked on a multitude of clinical development programs and in medical affairs in the UK and in South Africa for companies including Bristol Myers Squibb, Abbott Laboratories and Pharmacia. Dr. Lassen received her Medical Degree from the University of the Witwatersrand in South Africa and holds a Science degree in microbiology and physiology from the University of South Africa. She will lead the clinical development activities at Cytos.

Cheryl Lassen , MD, commented: "I am looking forward to leading the clinical development of CYT003, which is a first-in-class, unique immune modulator in development for the asthma indication. The clinical data from the Phase 2a study achieved its primary endpoint for asthma control and all other clinical endpoints were also met. This is an excellent basis to build the development program."

Philipp Mueller , MD, the current Executive Vice President Clinical Development will retire at the end of March 2013 and will continue to support the company as a consultant thereafter. Philipp joined in 2003 from Novartis and was responsible for all clinical development activities of Cytos during his tenure.

Philipp Mueller , MD, commented: "I am delighted to see the CYT003 project move from successful proof of concept to full development and would like to thank investigators and patients who participated in our studies, as well the teams at Cytos and external partner firms for their commitment and support."

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a first-in-class biologic in Phase 2 clinical development as a potential new treatment for allergic asthma.

CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body's immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function and asthma control in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

http://www.cytos.com

This foregoing press release may contain forward-looking statements that include words or phrases such as "are intended for", "are designed to", or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.


'/>"/>
SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Pioneer and Mendel Biotechnology, Inc. Collaborate to Improve Water Use Efficiency and Photosynthesis in Corn
2. Computer Review Announces New Tools to Deal with the Flood of Information from the Biotechnology Sector
3. Programs for Training in Biotechnology and Training Women in Bioscience and Biotechnology Careers
4. Research and Markets: Nanobiotechnology Applications, Markets and Companies - 2013 Report
5. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
6. Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
7. Biotechnology guaranteed US$ 100 K to average Brazilian corn growers in four years, according to ABRASEM
8. Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
9. 2012 Cotton Biotechnology Award Recipients
10. Biotechnology: Global Industry Guide
11. Riveting Biotechnology Novel, WIRED, Becomes the #1 Technothriller on Amazon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 CytRx Corporation (NASDAQ: ... in oncology, today announced the appointment of Earl ... consultant, and private healthcare investor, to its Board of ... with clinical and strategic experience at the highest level," ... CEO. "As one of the world,s leading orthopedic surgeons, ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom Healthcare ( ... hospitals, will present its chain-of-custody solution for tracking and securing medications at booth ... Dec. 4-8, 2016. , Aerocom has a proven solution for tracking medications via ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... Nanowear on their recent FDA Class II 510(k) clearance for their flagship medical ... in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. While other ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
Breaking Biology News(10 mins):